effect of laser therapy on symptoms of chemotherapy induced neuropathy
Not Applicable
Recruiting
- Conditions
- hemotherapy-induced neuropathy.
- Registration Number
- IRCT20240107060640N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Cancer patients who took the following chemotherapy drugs during treatment: 1. Platinum compounds 2. Vinca alkaloids3. Bortezomib 4. Taxans 5. Fluorouracil6. Thalidomide, lenalidomide
At least 6 months have passed since the end of the patient's chemotherapy.
The signs and symptoms of the disease have caused a decrease in the patient's quality of life.
Filling out the Toronto questionnaire
Exclusion Criteria
Entry into the study is subject to the absence of neuropathy due to other causes of neuropathy, including diabetes, radiculopathies, hereditary and acquired neuropathies, which can be verified at the beginning of the study through history and NCV.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method creasing the score obtained in the Toronto questionnaire based on history and examination and improvement of nerve conduction. Timepoint: History and examination and nerve conduction test at the beginning of the study and two weeks after the end of laser therapy. Method of measurement: Oronto neuropathy questionnaire and nerve conduction test.
- Secondary Outcome Measures
Name Time Method